Response to "The need for validation of MI GPSai in patients with CUP: Comment on: "Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type" | Caris Life Sciences
Portal
Order
Home / Research / Publications / Response to “The need for validation of MI GPSai in patients with CUP: Comment on: “Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type”

Publications

Back

Response to “The need for validation of MI GPSai in patients with CUP: Comment on: “Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type”

– Caris Life Sciences

Manuscript

Response to “The need for validation of MI GPSai in patients with CUP: Comment on: “Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type”

Read the Full Manuscript

Discover
More

  • Spliceosome Mutations in Metastatic Breast Cancer An Analysis of a Decentralized Clinical Trial and Large Clinical Genomic Dataset

    – Caris Life Sciences

    Poster

    […]

  • Molecular landscape of HR+/HER2- male breast cancer (MaBC) compared with female breast cancer (FeBC)

    – Caris Life Sciences

    Poster

    […]
Learn More

Ready to Get Started on the Journey?

Name(Required)